[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[3]
|
Salama, S., Diaz-Arrastia, C., Patel, D., et al. (2011) 2-Methoxyestradiol, an Endogenous Estrogen Metabolite, Sensitizes Radioresistant MCF-7/FIR Breast Cancer Cells through Multiple Mechanisms. International Journal of Radiation Oncology, Biology, Physics, 80, 231-239. https://doi.org/10.1016/j.ijrobp.2010.10.080
|
[4]
|
Hellmann, M.D., Paz-Ares, L., Bernabe, C.R., et al. (2019) Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 381, 2020-2031. https://doi.org/10.1056/NEJMoa1910231
|
[5]
|
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England Journal of Medicine, 373, 23-34. https://doi.org/10.1056/NEJMoa1504030
|
[6]
|
Konishi, J., Yamazaki, K., Azuma, M., et al. (2004) B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression. Clinical Cancer Research, 10, 5094-5100.
https://doi.org/10.1158/1078-0432.CCR-04-0428
|
[7]
|
Nomi, T., Sho, M., Akahori, T., et al. (2007) Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer. Clinical Cancer Research, 13, 2151-2157.
https://doi.org/10.1158/1078-0432.CCR-06-2746
|
[8]
|
Keir, M.E., Butte, M.J., Freeman, G.J., et al. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. https://doi.org/10.1146/annurev.immunol.26.021607.090331
|
[9]
|
Gong, J., Chehrazi-Raffle, A., Reddi, S., et al. (2018) Development of PD-1 and PD-L1 Inhibitors as a Form of Cancer Immunotherapy: A Comprehensive Review of Registration Trials and Future Considerations. Journal for ImmunoTherapy of Cancer, 6, 8. https://doi.org/10.1186/s40425-018-0316-z
|
[10]
|
Allaire, J.C., Balk, M., Azmi, S., et al. (2021) Use of PD-1 and PD-L1 Inhibitors after First-Line Therapy in Esophageal Cancer Patients in the US. Current Medical Research and Opinion, 37, 1403-1407.
https://doi.org/10.1080/03007995.2021.1929134
|
[11]
|
Gough, M.J., Sharon, S., Crittenden, M.R., et al. (2020) Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy. Seminars in Radiation Oncology, 30, 158-172.
https://doi.org/10.1016/j.semradonc.2019.12.002
|
[12]
|
Kwok, G., Yau, T.C., Chiu, J.W., et al. (2016) Pembrolizumab (Keytruda). Human Vaccines & Immunotherapeutics, 12, 2777-2789. https://doi.org/10.1080/21645515.2016.1199310
|
[13]
|
Sun, J.M., Shen, L., Shah, M.A., et al. (2021) Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. The Lancet, 398, 759-771. https://doi.org/10.1016/S0140-6736(21)01234-4
|
[14]
|
Kato, K., Shah, M.A., Enzinger, P., et al. (2019) KEYNOTE-590: Phase III Study of First-Line Chemotherapy with or without Pembrolizumab for Advanced Esophageal Cancer. Future Oncology, 15, 1057-1066.
https://doi.org/10.2217/fon-2018-0609
|
[15]
|
Doi, T., Piha-Paul, S.A., Jalal, S.I., et al. (2018) Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients with Advanced Esophageal Carcinoma. Journal of Clinical Oncology, 36, 61-67.
https://doi.org/10.1200/JCO.2017.74.9846
|
[16]
|
Lu, Z., Zou, J., Hu, Y., et al. (2019) Serological Markers Associated with Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. JAMA Network Open, 2, e197621.
https://doi.org/10.1001/jamanetworkopen.2019.7621
|
[17]
|
潘锋. 化疗联合免疫是未来食管癌治疗的发展方向——访北京大学肿瘤医院副院长沈琳教授[J]. 中国医药导报, 2020, 17(30): 1-3.
|
[18]
|
Creemers, A., Ebbing, E.A., Hooijer, G., et al. (2018) The Dynamics of HER2 Status in Esophageal Adenocarcinoma. Oncotarget, 9, 26787-26799. https://doi.org/10.18632/oncotarget.25507
|
[19]
|
Gerson, J.N., Skariah, S., Denlinger, C.S., et al. (2017) Perspectives of HER2-Targeting in Gastric and Esophageal Cancer. Expert Opinion on Investigational Drugs, 26, 531-540. https://doi.org/10.1080/13543784.2017.1315406
|
[20]
|
Janjigian, Y.Y., Maron, S.B., Chatila, W.K., et al. (2020) First-Line Pembrolizumab and Trastuzumab in HER2-Positive Oesophageal, Gastric, or Gastro-Oesophageal Junction Cancer: An Open-Label, Single-Arm, Phase 2 Trial. The Lancet Oncology, 21, 821-831. https://doi.org/10.1016/S1470-2045(20)30169-8
|
[21]
|
Zhang, B., Qi, L., Wang, X., et al. (2020) Phase II Clinical Trial Using Camrelizumab Combined with Apatinib and Chemotherapy as the First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma. Cancer Communications, 40, 711-720. https://doi.org/10.1002/cac2.12119
|
[22]
|
Yan, Z., Yao, Z.H., Yao, S.N., et al. (2020) Camrelizumab plus Apatinib Successfully Treated a Patient with Advanced Esophageal Squamous Cell Carcinoma. Immunotherapy, 12, 1161-1166. https://doi.org/10.2217/imt-2020-0197
|
[23]
|
Sun, S., Kim, J.J. and Ko, Y.H. (2019) CheckMate-032 Study: Promising Efficacy with Nivolumab-Based Immunotherapy in Pretreated Esophagogastric Cancer. Journal of Thoracic Disease, 11, S394-S395.
https://doi.org/10.21037/jtd.2018.12.02
|
[24]
|
Chau, I., Doki, Y., Ajani, J.A., et al. (2021) Nivolumab (NIVO) plus Ipilimumab (IPI) or NIVO plus Chemotherapy (Chemo) versus Chemo as First-Line (1L) Treatment for Advanced Esophageal Squamous Cell Carcinoma (ESCC): First Results of the CheckMate 648 Study. Journal of Clinical Oncology, 39, A4001.
https://doi.org/10.1200/JCO.2021.39.15_suppl.LBA4001
|
[25]
|
Minami, H., Kiyota, N. and Omori, T. (2021) Did the Randomized Phase III KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer Yield Negative or Positive Results? Journal of Clinical Oncology, 39, 2317-2318.
https://doi.org/10.1200/JCO.20.03262
|
[26]
|
Muro, K., Kojima, T., Moriwaki, T., et al. (2021) Second-Line Pembrolizumab versus Chemotherapy in Japanese Patients with Advanced Esophageal Cancer: Subgroup Analysis from KEYNOTE-181. Esophagus.
https://doi.org/10.1007/s10388-021-00877-3
|
[27]
|
Kudo, T., Hamamoto, Y., Kato, K., et al. (2017) Nivolumab Treatment for Oesophageal Squamous-Cell Carcinoma: An Open-Label, Multicentre, Phase 2 Trial. The Lancet Oncology, 18, 631-639.
https://doi.org/10.1016/S1470-2045(17)30181-X
|
[28]
|
Mehnert, J.M., Varga, A., Brose, M.S., et al. (2019) Safety and Antitumor Activity of the Anti-PD-1 Antibody Pembrolizumab in Patients with Advanced, PD-L1-Positive Papillary or Follicular Thyroid Cancer. BMC Cancer, 19, 196.
https://doi.org/10.1186/s12885-019-5380-3
|
[29]
|
Kelly, R.J., Ajani, J.A., Kuzdzal, J., et al. (2021) Adjuvant Nivolumab (NIVO) in Resected Esophageal or Gastroesophageal Junction Cancer (EC/GEJC) Following Neoadjuvant Chemoradiotherapy (CRT): Expanded Efficacy and Safety Analyses from CheckMate 577. Journal of Clinical Oncology, 39, 4003.
https://doi.org/10.1200/JCO.2021.39.15_suppl.4003
|